

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934
Release No. 68040 / October 11, 2012

ADMINISTRATIVE PROCEEDING
File No. 3-15062

In the Matter of

**CHINA MEDICAL
TECHNOLOGIES, INC.,**

Respondent.

**ORDER INSTITUTING PROCEEDINGS
PURSUANT TO SECTION 12(j) OF THE
SECURITIES EXCHANGE ACT OF 1934
AND NOTICE OF HEARING**

I.

The Securities and Exchange Commission (“Commission”) deems it necessary and appropriate for the protection of investors that public administrative proceedings be, and hereby are, instituted pursuant to Section 12(j) of the Securities Exchange Act of 1934 (“Exchange Act”) against China Medical Technologies, Inc. (“China Medical” or “Respondent”).

II.

After an investigation, the Division of Enforcement alleges that:

A. RESPONDENT

1. China Medical is a Cayman Islands corporation located in the People’s Republic of China that purports to develop, manufacture and market medical devices. In 2005, China Medical registered its ordinary shares pursuant to Section 12(g) of the Exchange Act and registered an initial public offering of American Depositary Shares (“ADSs”) (each of which represented ten ordinary shares), which were quoted on the Nasdaq National Market. In 2006, after Nasdaq Stock Market LLC became a registered national securities exchange, the ordinary shares became registered pursuant to Section 12(b) of the Exchange Act, and the ADSs became listed on the Nasdaq Global Select Market (“Nasdaq”). On March 14, 2012, Nasdaq filed a Form 25, pursuant to which the China Medical ADSs were delisted effective March 26, 2012, and the ordinary shares were deregistered from Section 12(b) effective June 12, 2012. At that point, the ordinary shares reverted to their previous Section 12(g) registration. China Medical ADSs are currently quoted on OTC Link (f.k.a. “the Pink Sheets”) operated by OTC Markets Group Inc. and quote under the ticker symbol “CMEDY.” China Medical identifies itself as a foreign private issuer under the

Exchange Act and has filed and furnished reports with the Commission on Forms 20-F and 6-K. As of July 27, 2012, pursuant to an Order by the Grand Court of the Cayman Islands, China Medical has been under the control of Joint Official Liquidators.

B. DELINQUENT PERIODIC FILING

2. Section 13(a) of the Exchange Act and Rule 13a-1 thereunder require issuers with classes of securities registered pursuant to Section 12 of the Exchange Act to file annual reports with the Commission.

3. China Medical has failed to comply with Section 13(a) of the Exchange Act and Rule 13a-1 thereunder, while its securities were registered with the Commission pursuant to Section 12 of the Exchange Act, in that it has not filed an Annual Report on Form 20-F since July 18, 2011.

III.

In view of the allegations made by the Division of Enforcement, the Commission deems it necessary and appropriate for the protection of investors that public administrative proceedings be instituted to determine:

A. Whether the allegations contained in Section II hereof are true and, in connection therewith, to afford Respondent an opportunity to establish any defenses to such allegations; and,

B. Whether it is necessary and appropriate for the protection of investors to suspend for a period not exceeding twelve months, or revoke the registration of each class of securities registered pursuant to Section 12 of the Exchange Act of the Respondent identified in Section II hereof, and any successor under Exchange Act Rules 12b-2 or 12g-3, and any new corporate name of the Respondent.

IV.

IT IS HEREBY ORDERED that a public hearing for the purpose of taking evidence on the questions set forth in Section III hereof shall be convened at a time and place to be fixed, and before an Administrative Law Judge to be designated by further order as provided by Rule 110 of the Commission's Rules of Practice [17 C.F.R. § 201.110].

IT IS FURTHER ORDERED that Respondent shall file an Answer to the allegations contained in this Order within twenty (20) days after service of this Order, as provided by Rule 220 of the Commission's Rules of Practice [17 C.F.R. § 201.220].

If Respondent fails to file the directed Answer, or fails to appear at a hearing after being duly notified, the Respondent, and any successor under Exchange Act Rules 12b-2 or 12g-3, and any new corporate names of Respondent, may be deemed in default and the proceedings may be determined against it upon consideration of this Order, the allegations of which may be deemed to be true as

provided by Rules 155(a), 220(f), 221(f), and 310 of the Commission's Rules of Practice [17 C.F.R. §§ 201.155(a), 201.220(f), 201.221(f), and 201.310].

This Order shall be served forthwith upon Respondent personally or by certified, registered or Express Mail, or by other means permitted by the Commission's Rules of Practice.

IT IS FURTHER ORDERED that the Administrative Law Judge shall issue an initial decision no later than 120 days from the date of service of this Order, pursuant to Rule 360(a)(2) of the Commission's Rules of Practice [17 C.F.R. § 201.360(a)(2)].

In the absence of an appropriate waiver, no officer or employee of the Commission engaged in the performance of investigative or prosecuting functions in this or any factually related proceeding will be permitted to participate or advise in the decision of this matter, except as witness or counsel in proceedings held pursuant to notice. Since this proceeding is not "rule making" within the meaning of Section 551 of the Administrative Procedure Act, it is not deemed subject to the provisions of Section 553 delaying the effective date of any final Commission action.

By the Commission.

Elizabeth M. Murphy
Secretary